Notice: This company has been marked as potentially delisted and may not be actively trading. Alpine Immune Sciences (ALPN) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipTrends Get the Latest News and Ratings for ALPN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Alpine Immune Sciences and its competitors. Enter your email to sign up for newsletter Sign Up ALPN Analyst Ratings Over TimeTypeCurrent Forecast1/3/24 to 1/2/251 Month Ago12/4/23 to 12/3/243 Months Ago10/5/23 to 10/4/241 Year Ago1/3/23 to 1/3/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy2 Buy rating(s)2 Buy rating(s)3 Buy rating(s)6 Buy rating(s)Hold8 Hold rating(s)8 Hold rating(s)8 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$56.63$56.63$52.33$25.00Forecasted Upside-12.84% Downside-12.84% Downside-19.45% Downside35.14% UpsideConsensus RatingHoldHoldHoldBuy URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now ALPN Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ALPN Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Alpine Immune Sciences Stock vs. The CompetitionTypeAlpine Immune SciencesMedical CompaniesS&P 500Consensus Rating Score 2.20 2.81 2.51Consensus RatingHoldModerate BuyModerate BuyPredicted Upside-12.84% Downside24,318.19% Upside14.95% UpsideNews Sentiment RatingNeutral NewsSee Recent ALPN NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails5/16/2024Wedbush4 of 5 starsR. DriscollSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$65.00+0.05%4/16/2024TD Cowen5 of 5 stars Reiterated RatingBuy ➝ Hold4/12/2024Leerink Partners1 of 5 stars DowngradeOutperform ➝ Market Perform$42.00 ➝ $65.00+0.87%4/11/2024Leerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingT. SmithSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/11/2024HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingJ. PantginisSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/11/2024Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $65.00+38.18% Get the Latest News and Ratings for ALPN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter. 4/11/2024Royal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOutperform ➝ Sector Perform$41.00 ➝ $65.00+38.18%4/11/2024Wolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOutperform ➝ Peer Perform4/9/2024GuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageBuy$55.00+42.75%3/19/2024OppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOutperform ➝ Outperform$33.00 ➝ $44.00+24.05%10/17/2023Berenberg BankSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageBuy$18.00+80.00%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:36 AM ET. ALPN Forecast - Frequently Asked Questions What is Alpine Immune Sciences' forecast for 2025? According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Alpine Immune Sciences is $56.63, with a high forecast of $65.00 and a low forecast of $44.00. Should I buy or sell Alpine Immune Sciences stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last twelve months. There are currently 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALPN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALPN, but not buy additional shares or sell existing shares. Does Alpine Immune Sciences's stock price have much downside? According to analysts, Alpine Immune Sciences's stock has a predicted downside of -12.84% based on their 12-month stock forecasts. Do Wall Street analysts like Alpine Immune Sciences more than its competitors? Analysts like Alpine Immune Sciences less than other "medical" companies. The consensus rating for Alpine Immune Sciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ALPN compares to other companies. Stock Forecasts and Research Tools Related Companies UTHR Stock Forecast RPRX Stock Forecast VTRS Stock Forecast GMAB Stock Forecast SMMT Stock Forecast RDY Stock Forecast BMRN Stock Forecast INSM Stock Forecast SRPT Stock Forecast CTLT Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol This page (NASDAQ:ALPN) was last updated on 1/2/2025 by MarketBeat.com Staff From Our Partners3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpine Immune Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alpine Immune Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
